ASCO QTP project to improve equity in cancer clinical trials.
Abstract
578 Background: Clinical trials are a core component of high-quality cancer care, yet minority enrollment in oncology treatment trials at the University of Wisconsin Carbone Cancer Center (UWCCC) was 5.8% in 2023, which is lower than the Wisconsin cancer catchment rate of 9.6%. Methods: As part of the ASCO’s Quality Training Program (QTP) project in 2024, our multidisciplinary quality improvement (QI) team aimed to improve minority trial enrollment at the UWCCC by 30%, from 5.8% to 7.54% by 2026. The team launched a clinical trial patient education pilot in multi-disciplinary gastrointestinal (GI) clinics utilizing the nursing team. To provide clinical trial education across Wisconsin, the team partnered with the Cancer Health Disparities Initiative (CHDI) to reach the African American community and with the Planned Parenthood of Wisconsin Promotores de Salud Program to reach the Latine community. To enable ongoing high-quality data capture, we implemented an Epic SmartForm across UWCCC to capture and support reporting on trial offers and reasons for declining consent. Results: Between October and December 2024, 49 new patients with GI malignancies received trial education. In October 2025, 37 African American community members received trial education. Between January and May 2026, 595 Latine community members received education, which is ongoing, and a dedicated Latine patient navigator will be hired. The Epic SmartForm was piloted among three research teams in October 2025 and implemented across UWCCC in March 2026. Following implementation, 124 forms were completed through May 2026. These included 27 forms with no study offer (primary reason: known ineligibility, 15/27), 21 with no consent given (primary reason: prefer other treatment, 8/21), and 26 where consent was given but not signed (primary reason: prefer other treatment, 14/26). Overall, minority trial accrual improved from 5.8% in 2023 to 8.3% in 2024 and 10.4% in 2025. In the first quarter of 2026, minority accrual was 6.1%, based on limited data (N=8). Conclusions: A multidisciplinary QI approach pairing clinic- and community-based education with systematic data capture was associated with improved minority trial accrual, rising from 5.8% in 2023 to 8.3% in 2024 and 10.4% in 2025, surpassing the project goal. First-quarter of 2026 data are too limited to interpret, underscoring the need to sustain these interventions and monitor accrual over time. The Epic SmartForm now provides high-quality, ongoing data on trial offers and reasons for declining consent to guide future efforts. Minority participant accrual to treatment trials. Adult treatment trial enrollment 2021-Total 2022-Total 2023-Total 2024-Total 2025-Total 2026-Q1 N 31 26 25 35 42 8 % 6.7% 6.4% 5.8% 8.3% 10.4% 6.1%